Recently, a new report has shown that R-2HG treatment or FTO inhibition abrogates m6A/YTHDF2-mediated post-transcriptional up-regulation of two critical glycolytic genes PFKP and LDHB expressions, thereby reducing aerobic glycolysis and playing a critical tumor-promoting role in the pathogenesis of AML (Qing et al., 2021). The gene discussed is FTO; the disease is acute myeloid leukemia.